These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 18342814)

  • 1. Hematopoietic cell transplantation for patients with myelodysplastic syndromes (MDS): when, how and for whom?
    Marcondes M; Deeg HJ
    Best Pract Res Clin Haematol; 2008 Mar; 21(1):67-77. PubMed ID: 18342814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The evolution of hematopoietic SCT in myelodysplastic syndrome.
    Kindwall-Keller T; Isola LM
    Bone Marrow Transplant; 2009 Apr; 43(8):597-609. PubMed ID: 19252532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Progress of research on allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimen for treatment of myelodysplastic syndrome - review].
    Zhang Z; Li X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):969-74. PubMed ID: 18718102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hematopoietic cell transplantation for myelodysplastic syndrome.
    Deeg HJ
    Am Soc Clin Oncol Educ Book; 2015; ():e375-80. PubMed ID: 25993199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transplant strategies for patients with myelodysplastic syndromes.
    Deeg HJ
    Curr Opin Hematol; 2006 Mar; 13(2):61-6. PubMed ID: 16456370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current status of allogeneic hematopoietic cell transplantation for MDS.
    Xu F; Deeg HJ
    Curr Pharm Des; 2012; 18(22):3215-21. PubMed ID: 22571701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant.
    Ghosh N; Ahmed S; Ahn KW; Khanal M; Litovich C; Aljurf M; Bacher VU; Bredeson C; Epperla N; Farhadfar N; Freytes CO; Ganguly S; Haverkos B; Inwards D; Kamble RT; Lazarus HM; Lekakis L; Murthy HS; Nishihori T; Ramakrishnan P; Rizzieri DA; Yared JA; Kharfan-Dabaja MA; Sureda A; Hamadani M
    JAMA Oncol; 2020 Jul; 6(7):1011-1018. PubMed ID: 32496525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Haploidentical Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Grafts in Older Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome.
    Slade M; DiPersio JF; Westervelt P; Vij R; Schroeder MA; Romee R
    Biol Blood Marrow Transplant; 2017 Oct; 23(10):1736-1743. PubMed ID: 28688919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transplantation for myelodysplastic syndromes 2013.
    Vaughn JE; Scott BL; Deeg HJ
    Curr Opin Hematol; 2013 Nov; 20(6):494-500. PubMed ID: 24104409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of 10-Day Decitabine to Fludarabine/Total Body Irradiation Conditioning is Feasible and Induces Tumor-Associated Antigen-Specific T Cell Responses.
    Cruijsen M; Hobo W; van der Velden WJFM; Bremmers MEJ; Woestenenk R; Bär B; Falkenburg JHF; Kester M; Schaap NPM; Jansen J; Blijlevens NNM; Dolstra H; Huls G
    Biol Blood Marrow Transplant; 2016 Jun; 22(6):1000-1008. PubMed ID: 26860635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic hematopoietic cell transplantation for MDS: for whom, when and how?
    Gyurkocza B; Deeg HJ
    Blood Rev; 2012 Nov; 26(6):247-54. PubMed ID: 22981712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing stem cell transplantation in myelodysplastic syndromes: unresolved questions.
    Warlick ED
    Curr Opin Oncol; 2010 Mar; 22(2):150-4. PubMed ID: 20010295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning.
    Yucel OK; Saliba RM; Rondon G; Ahmed S; Alousi A; Bashir Q; Ciurea SO; Popat U; Khouri I; Marin D; Rezvani K; Kebriaei P; Shpall EJ; Champlin RE; Oran B
    Cancer; 2017 Jul; 123(14):2661-2670. PubMed ID: 28324640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of busulfan/cyclophosphamide versus busulfan/fludarabine myeloablative conditioning for allogeneic hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome.
    Patel SS; Rybicki L; Pohlman B; Bolwell B; Gerds AT; Hamilton BK; Hanna R; Kalaycio M; Majhail NS; Sobecks R
    Hematol Oncol Stem Cell Ther; 2020 Sep; 13(3):160-165. PubMed ID: 31628924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: current status.
    Deeg HJ; Bartenstein M
    Arch Immunol Ther Exp (Warsz); 2012 Feb; 60(1):31-41. PubMed ID: 22143157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization of transplant regimens for patients with myelodysplastic syndrome (MDS).
    Deeg HJ
    Hematology Am Soc Hematol Educ Program; 2005; ():167-73. PubMed ID: 16304376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome.
    Nakamura R; Rodriguez R; Palmer J; Stein A; Naing A; Tsai N; Chang K; Slovak ML; Bhatia R; Spielberger R; Kogut N; Pullarkat V; Kirschbaum M; Forman SJ; O'Donnell MR
    Bone Marrow Transplant; 2007 Nov; 40(9):843-50. PubMed ID: 17724447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transplantation for myelodysplastic syndromes: who, when, and which conditioning regimens.
    Saber W; Horowitz MM
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):478-484. PubMed ID: 27913519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.